Dementia rates in the US, UK, Netherlands, Sweden, France, and several other high-income countries have been falling for decades, despite population aging. The standard explanation — improved cardiovascular care, more education, and less smoking in later-born cohorts — is real but incomplete. Research Highlights Dementia incidence has been falling about 13% per decade in Western …
A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved hard: negative predictive value fell from 0.831 inside ADNI to 0.644 when the ADNI-trained model was applied to A4.1 Research Highlights 1,707-person ADNI/A4 test: researchers trained amyloid PET prediction models …
A 2026 TADPOLE modeling study reported that a sequential neural process with normalizing flows predicted future Alzheimer diagnostic stage with mAUC 0.965 ± 0.006, ahead of the authors’ earlier sequential-neural-process model at 0.937 ± 0.014.1 The result is a strong benchmark signal for uncertainty-aware disease-progression AI, but it is still retrospective modeling evidence rather than …
A 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural network that combined structural MRI regional features with clinical variables to classify cognitively normal controls, mild cognitive impairment, and Alzheimer’s disease.1 The result is useful, but the clinical-feature ablation dropped accuracy to 68.35%, so the model should be read as multimodal decision-support research, …
A 2026 Molecular Psychiatry study found that RVI-AD, a structural-MRI score measuring how closely a person’s brain anatomy matches an Alzheimer’s disease pattern, predicted mild-cognitive-impairment conversion to dementia most strongly over the next 3 years: OR 2.16, 95% CI 1.81-2.57, p < 2e-16, AUC 0.70.1 Research Highlights Short-term conversion signal: in 965 ADNI participants with …
Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …